- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Laurus Labs delivered strong Q1 FY27 financial results. Revenue hit ₹2,026 Cr, surging 29% YoY. EBITDA grew 66% YoY to ₹644 Cr, with margins expanding to 31.8%. Net Profit jumped 126% YoY to ₹368 Cr. This robust performance was largely driven by the CDMO segment's 67% YoY growth from commercial projects, supported by steady momentum in Affordable Medicines. The company continues significant CAPEX (19% of sales) into expanding manufacturing across API, FDF, Peptides, Fermentation, and Advanced Biologics. Management expresses confidence in sustained growth and diversified portfolio expansion.